The Puppe

RECEIVED CENTRAL FAX CENTER

OCT 0 6 2004

a collection of information unless it displays a valid OMS control number.

PTO/SB/26 (08-03)
Approved for use Brough 07/31/2006. OMB 0851-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
and to a collection of international control of the collection of the collectio

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING Docket Number (Optional) REJECTION OVER A PRIOR PATENT 219002030901 In re Application of: George F. SCHREINER et al. 10/083,817 Application No.: Fëed: February 26, 2002 For METHODS OF TREATING HYPERTENSION AND COMPOSITIONS FOR USE THEREIN Scios, Inc. and University of Washington , of combined percent interest in the instant application hereby discisions, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173. as presently shortened by any terminal disclaimer, of prior Patent No. 6,352,975 . The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the Instant application and is binding upon the grantee, its successors or assigns. in making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance see, is held unenforceable, is found invalid by a court of competent jurisdiction, is atalistorily disclaimed in whole or terminatly disclaimed under 37 CFR 1,321, has all claims canceled by a reexamination conflicate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer. Check either box 1 or 2 below, if appropriate. For submissions on bahalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization. I hereby declare that all statements made harein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false atsterrents and the lits so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. The undersigned is an attorney or agent of record October 6, 2004 Date James J. Müllen III, Ph.D. - 44,957 Typed or printed name (858) 720-7940 Telephone Number 0/12/2004 GTRAHHEL 0000 002 3 Terminal discharmer fee under 37 CFR 1.20(d) is included. 10083817 "Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). 110.00 DA Form PTO/SB/96 may be used for making this certification. See MPEP § 324. I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office at (703) 872-9308, on Dated: October 6, 2004 Signature: (Grace Yu)

sd-223902

1 FC:1814